Istituto Nazionale Tumori

AccuStem's MSC Blood Test Set to Transform Lung Cancer Screening in the US

- AccuStem Sciences plans to launch its microRNA Signature Classifier (MSC) blood test for 1.6 million US patients diagnosed annually with lung nodules, with potential expansion to 15 million at-risk individuals. - Clinical trials involving over 5,000 patients demonstrated that combining MSC with low-dose CT scanning reduced false positive rates from 19.4% to 3.7%, representing a five-fold improvement in accuracy. - The BioMILD trial showed MSC-positive patients are four times more likely to have or develop lung cancer compared to MSC-negative patients, potentially reducing unnecessary biopsies and healthcare costs.